11:33 AM
 | 
Oct 10, 2018
 |  BC Extra  |  Preclinical News

Quentis links ER stress, mitochondrial dysfunction with antitumor T cell activity

Researchers at Quentis Therapeutics Inc. (New York, N.Y.), Weill Cornell Medicine and Dana-Farber Cancer Institute uncovered a new mechanism of tumor immune evasion in which endoplasmic reticulum stress limits mitochondrial respiration and antitumor activity in T cells, suggesting that inhibiting the ER stress response could boost T cell activity against ovarian cancer.

Quentis, co-founded by authors Laurie Glimcher and Juan Cubillos-Ruiz, is developing potentially first-in-class...

Read the full 302 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >